A recent study using 5XFAD mice, an AD model with massive cerebral Aβ deposits, shows that VIP intraperitoneal chronic administration significantly decreases Aβ accumulation and reduces the atrophy in brain regions involved in cognition, such as hippocampus and cortex (Korkmaz et al., 2019). Here, VIP is linked to Alzheimer disease.